Bazedoxifene

Modify Date: 2024-01-03 01:16:02

Bazedoxifene structure	Common Name	Bazedoxifene
	CAS Number	198481-32-2	Molecular Weight	470.603
	Density	1.2±0.1 g/cm3	Boiling Point	694.4±55.0 °C at 760 mmHg
	Molecular Formula	C₃₀H₃₄N₂O₃	Melting Point	N/A
	MSDS	N/A	Flash Point	373.8±31.5 °C

Use of Bazedoxifene

Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment.IC50 value:Target: estrogen receptor modulatorPreclinical and clinical studies with bazedoxifene demonstrate more tissue selectivity than other SERMs. In particular, bazedoxifene has minimal if any agonist activity in the uterus and is able to antagonize effects of estrogen on the uterus. Animal studies and early clinical studies suggest effects in the bone similar to other SERMs with prevention of postmenopausal bone loss.

Name	1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
Synonym	More Synonyms

Description	Bazedoxifene is a selective estrogen receptor modulator (SERM) currently in development for osteoporosis prevention and treatment.IC50 value:Target: estrogen receptor modulatorPreclinical and clinical studies with bazedoxifene demonstrate more tissue selectivity than other SERMs. In particular, bazedoxifene has minimal if any agonist activity in the uterus and is able to antagonize effects of estrogen on the uterus. Animal studies and early clinical studies suggest effects in the bone similar to other SERMs with prevention of postmenopausal bone loss.
Related Catalog	Signaling Pathways >> Others >> Estrogen Receptor/ERR Research Areas >> Cancer
References	[1]. Lewis-Wambi JS, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. Mol Pharmacol. 2011 Oct;80(4):610-20. [2]. Duggan ST, McKeage K. Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. Drugs. 2011 Nov 12;71(16):2193-212. [3]. Lello S, Brandi ML, Minisola G et al. Bazedoxifene: literature data and clinical evidence. Clin Cases Miner Bone Metab. 2011 Sep;8(3):29-32. [4]. Komm BS, Chines AA. Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2012 Feb;4(1):21-34.

Description

Related Catalog

Signaling Pathways >> Others >> Estrogen Receptor/ERR

Research Areas >> Cancer

References

[1]. Lewis-Wambi JS, et al. The selective estrogen receptor modulator bazedoxifene inhibits hormone-independent breast cancer cell growth and down-regulates estrogen receptor α and cyclin D1. Mol Pharmacol. 2011 Oct;80(4):610-20.

[2]. Duggan ST, McKeage K. Bazedoxifene: a review of its use in the treatment of postmenopausal osteoporosis. Drugs. 2011 Nov 12;71(16):2193-212.

[3]. Lello S, Brandi ML, Minisola G et al. Bazedoxifene: literature data and clinical evidence. Clin Cases Miner Bone Metab. 2011 Sep;8(3):29-32.

[4]. Komm BS, Chines AA. Bazedoxifene: the evolving role of third-generation selective estrogen-receptor modulators in the management of postmenopausal osteoporosis. Ther Adv Musculoskelet Dis. 2012 Feb;4(1):21-34.

Density	1.2±0.1 g/cm3
Boiling Point	694.4±55.0 °C at 760 mmHg
Molecular Formula	C₃₀H₃₄N₂O₃
Molecular Weight	470.603
Flash Point	373.8±31.5 °C
Exact Mass	470.256958
PSA	57.86000
LogP	6.59
Vapour Pressure	0.0±2.3 mmHg at 25°C
Index of Refraction	1.622
Storage condition	2-8℃

Precursor 7
CAS#:198480-21-6 1-[4-(2-AZEPAN-... CAS#:1072-21-5 Adipaldehyde CAS#:111-49-9 Azepane CAS#:623-05-2 4-Hydroxybenzyl...
CAS#:35081-45-9 4'-(Benzyloxy)-... CAS#:198479-63-9 3-methyl-5-phen... CAS#:51388-20-6 4-Benzyloxyanil...
DownStream 0